Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research Article
  • Published:

Hyperprolinemia is a risk factor for schizoaffective disorder

Abstract

DNA sequence variations within the 22q11 DiGeorge chromosomal region are likely to confer susceptibility to psychotic disorders. In a previous report, we identified several heterozygous alterations, including a complete deletion, of the proline dehydrogenase (PRODH) gene, which were associated with moderate hyperprolinemia in a subset of DSM III schizophrenic patients. Our objective was (i) to determine whether hyperprolinemia is associated with increased susceptibility for any of three psychiatric conditions (schizophrenia, schizoaffective disorder and bipolar disorder) and (ii) to establish a correlation between hyperprolinemia and PRODH genotypes. We have conducted a case–control study including 114 control subjects, 188 patients with schizophrenia, 63 with schizoaffective disorder and 69 with bipolar disorder. We report that, taking into account a confounding effect due to valproate treatment, hyperprolinemia is a risk factor for DSM IIIR schizoaffective disorder (P=0.02, Odds ratio=4.6, 95% confidence interval 1.3–16.3). We did not detect 22q11 interstitial deletions associated with the DiGeorge syndrome among the 320 patients of our sample and we found no association between common PRODH polymorphisms and any of the psychotic disorders. In contrast, we found that five rare PRODH alterations (including a complete PRODH deletion and four missense substitutions) were associated with hyperprolinemia. In several cases, two variations were present simultaneously, either in cis or trans in the same subject. A total of 11 from 30 hyperprolinemic subjects bore at least one genetic variation associated with hyperprolinemia. This study demonstrates that moderate hyperprolinemia is an intermediate phenotype associated with certain forms of psychosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sporn A, Addington A, Reiss AL, Dean M, Gogtay N, Potocnick U et al. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry 2004; 9: 225–226.

    Article  CAS  Google Scholar 

  2. Murphy KC, Jones LA, Owen MJ . High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999; 56: 940–945.

    Article  CAS  Google Scholar 

  3. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 1996; 153: 1541–1547.

    Article  CAS  Google Scholar 

  4. Scambler PJ . The 22q11 deletion syndromes. Hum Mol Genet 2000; 9: 2421–2426.

    Article  CAS  Google Scholar 

  5. Carlson C, Sirotkin H, Pandita R, McKie J, Wadey R, Patanjali SR et al. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum Genet 1997; 61: 620–629.

    Article  CAS  Google Scholar 

  6. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet 2002; 11: 2243–2249.

    Article  CAS  Google Scholar 

  7. Jacquet H, Berthelot J, Bonnemains C, Simard G, Saugier-Veber P, Raux G et al. The severe form of type I hyperprolinaemia results from homozygous inactivation of the PRODH gene. J Med Genet 2003; 40: e7.

    Article  CAS  Google Scholar 

  8. Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.

    Article  CAS  Google Scholar 

  9. Fyer AJ, Endicott J, Manuzza S, Klein DF . Schedule for Affective Disorders and Schizophrenia, Lifetime Version Modified for the Study of Anxiety Disorders. Anxiety Genetics Unit, New York State Psychiatric Institute: New York, 1985.

    Google Scholar 

  10. Zhao JH, Curtis D, Sham PC . Model-free analysis and permutation tests for allelic associations. Hum Hered 2000; 50: 121–128.

    Article  Google Scholar 

  11. Bremer HJ, Duran M, Przyrembel H, Wadman SK . Disturbances of Amino Acid Metabolism: Clinical Chemistry and Diagnosis. Urban and Schwarwenberg: Baltimore–Munich, 1981.

    Google Scholar 

  12. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002; 99: 3717–3722.

    Article  CAS  Google Scholar 

  13. De Vane CL . Pharmacokinetics, drugs interactions, and tolerability of Valproate. Psychopharmacol Bull 2003; 37: 25–42.

    Google Scholar 

  14. Kasanin J . The acute schizoaffective psychoses. Am J Psychiatry 1933; 13: 97–126.

    Article  Google Scholar 

  15. Kendler KS, McGuire M, Gruenberg AM, Walsh D . Examining the validity of DSM-III-R schizoaffective disorder and its putative subtypes in the Roscommon family study. Am J Psychiatry 1995; 152: 755–764.

    Article  CAS  Google Scholar 

  16. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P . A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002; 159: 539–545.

    Article  Google Scholar 

  17. Maier W, Lichtermann D, Minges J, Hallmayer J, Heun R, Benkert O et al. Continuity and discontinuity of affective disorders and schizophrenia. Arch Gen Psychiatry 1993; 50: 871–883.

    Article  CAS  Google Scholar 

  18. Gershon ES, DeLisi LE, Hamovit J, Nurnberger JI, Maxwell ME, Schreiber J et al. A controlled family study of chronic psychoses. Arch Gen Psychiatry 1988; 45: 328–336.

    Article  CAS  Google Scholar 

  19. Williams HJ, Williams N, Spurlock G, Norton N, Ivanov D, McCreadie RG et al. Association between PRODH and schizophrenia is not confirmed. Mol Psychiatry 2003; 8: 644–645.

    Article  CAS  Google Scholar 

  20. Williams HJ, Williams N, Spurlock G, Norton N, Zammit S, Kirov G et al. Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia. Am J Med Genet 2003; 120B: 42–46.

    Article  CAS  Google Scholar 

  21. Ohtsuki T, Tanaka S, Ishiguro H, Noguchi E, Arinami T . Failure to find association between PRODH deletion and schizophrenia. Schizophr Res 2004; 67: 111–113.

    Article  Google Scholar 

  22. Arinami T, Ohtsuki T, Takase K, Shimizu H, Yoshikawa T, Horigome H et al. Screening for 22q11 deletions in a schizophrenia population. Schizophr Res 2001; 52: 167–170.

    Article  CAS  Google Scholar 

  23. Ivanov D, Kirov G, Norton N, Williams HJ, Williams NM, Nikolov I et al. Chromosome 22q11 deletions, velo-cardio-facial syndrome and early-onset psychosis. Molecular genetic study. Br J Psychiatry 2003; 183: 409–413.

    Article  CAS  Google Scholar 

  24. Karayiorgou M, Morris MA, Morrow BE, Shprintzen RJ, Goldberg R, Borrow J et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 1995; 92: 7612–7616.

    Article  CAS  Google Scholar 

  25. Goodman BK, Rutberg J, Lin WW, Pulver AE, Thomas GH, Geraghty MT . Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J Inherit Metab Dis 2000; 23: 847–848.

    Article  CAS  Google Scholar 

  26. Nadler JV, Wang A, Hakim A . Toxicity of L-proline toward rat hippocampal neurons. Brain Res 1988; 456: 168–172.

    Article  CAS  Google Scholar 

  27. Cohen SM, Nadler JV . Proline-induced potentiation of glutamate transmission. Brain Res 1997; 761: 271–282.

    Article  CAS  Google Scholar 

  28. Pontes ZL, Oliveira LS, Franzon R, Wajner M, Wannmacher CM, Wyse AT . Inhibition of Na+, K+-ATPase activity from rat hippocampus by proline. Neurochem Res 2001; 26: 1321–1326.

    Article  CAS  Google Scholar 

  29. Delwing D, Bavaresco CS, Wannmacher CM, Wajner M, Dutra-Filho CS, Wyse AT . Proline induces oxidative stress in cerebral cortex of rats. Int J Dev Neurosci 2003; 21: 105–110.

    Article  CAS  Google Scholar 

  30. Delwing D, Bavaresco CS, Chiarani F, Wannmacher CM, Wajner M, Dutra-Filho CS et al. In vivo and in vitro effects of proline on some parameters of oxidative stress in rat brain. Brain Res 2003; 991: 180–186.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

HJ was supported by a grant from the Ministère de la Recherche. CD was supported by la Fondation pour la Recherche Medicale. We are indebted to our colleagues who referred patients for this study. We thank the technicians from the Department of Biochemistry for their helpful assistance. We thank R Lalonde and M Martinez for their help. We are grateful to Pr D Valle and Dr HU Bender for communication of unpublished results.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Campion.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacquet, H., Demily, C., Houy, E. et al. Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 10, 479–485 (2005). https://doi.org/10.1038/sj.mp.4001597

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001597

Keywords

This article is cited by

Search

Quick links